About Ocrelizumab
            
            Class: | Monoclonal antibody (anti-CD20)  
Use: | Treatment of relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS)  
Adult dose: | Initial dose: 300 mg IV on Day 1, followed by 300 mg IV two weeks later (Day 15); subsequent doses: 600 mg IV every six months  
Pediatric dose: | Safety and efficacy not established in pediatric patients  
Side effects: | Infusion-related reactions, infections, headache, fatigue, nausea, rash  
Contraindications: | Active hep
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody (anti-CD20)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS)
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze; protect from light
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: F. Hoffmann-La Roche Ltd [Basel;Switzerland], Switzerland
                    
                    
                    Package Size
                    1's Glass Vial [23ml]
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 53602.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        Initial dose: 300 mg IV on Day 1, followed by 300 mg IV two weeks later (Day 15); subsequent doses: 600 mg IV every six months
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy not established in pediatric patients
                    
                 
                
                
                    
                        Side Effects
                    
                    Infusion-related reactions, infections, headache, fatigue, nausea, rash
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Active hepatitis B infection, known hypersensitivity to ocrelizumab or any component of the formulation
         
        
        
            
                Important Warnings
            
            Risk of serious infections, including progressive multifocal leukoencephalopathy (PML); monitor for signs of infection; premedication with antihistamines and corticosteroids recommended to reduce infusion-related reactions
         
        
        
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.